ABO incompatible platelets: risks versus benefit

Purpose of reviewThe importance of ABO blood group system compatibility in platelet transfusion is a subject of ongoing debate. Although there are theoretical advantages to pursuing a strict policy of providing exclusively ABO-compatible products, resource challenges may make this untenable for many transfusion services. Moreover, data supporting a net clinical benefit for this practice have been lacking. This review summarizes recent developments in the area of ABO compatibility and platelet transfusion and examines the risks and benefits associated with transfusion practices allowing for platelet ABO incompatibility. Recent findingsABO-major incompatible transfusions are associated with lower platelet count increments than either ABO identical or minor incompatible transfusions and may lead to decreased intervals between platelet transfusions in thrombocytopenic patients. ABO-minor incompatible transfusions may rarely result in acute hemolytic reactions that are not predicted by isohemagglutinin titers. Yet published evidence to date does not clearly demonstrate improvements in clinical outcomes for patients receiving ABO-identical or ABO-compatible platelets. Adherence to a strict policy of transfusing exclusively ABO-identical platelets may lead to an increase in product wastage and challenges in maintaining adequate platelet availability. SummaryThere is presently limited data and no consensus on the best approach for managing ABO compatibility in platelet transfusions. Well designed, sufficiently powered randomized clinical trials are urgently needed. These studies must examine not only safety and efficacy of various ABO matching strategies but also clinical benefit and resource utilization in order to identify optimal platelet transfusion strategies.

[1]  S. Spinelli,et al.  Alterations of platelet function and clot formation kinetics after in vitro exposure to anti‐A and ‐B , 2013, Transfusion.

[2]  A. Tobian,et al.  ABO antibody titers are not predictive of hemolytic reactions due to plasma‐incompatible platelet transfusions , 2012, Transfusion.

[3]  S. Anderson,et al.  Outpatient transfusions and occurrence of serious noninfectious transfusion‐related complications among US elderly, 2007‐2008: utility of large administrative databases in blood safety research , 2012, Transfusion.

[4]  S. Assmann,et al.  The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. , 2012, Blood.

[5]  J. G. van der Bom,et al.  A comparison of volume‐reduced versus standard HLA/HPA–matched apheresis platelets in alloimmunized adult patients , 2012, Transfusion.

[6]  C. Paupairoj,et al.  Preparation of single donor platelet with low antibody titers for all patients. , 2012, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[7]  N. Blumberg,et al.  Providing ABO‐identical platelets and cryoprecipitate to (almost) all patients: approach, logistics, and associated decreases in transfusion reaction and red blood cell alloimmunization incidence , 2012, Transfusion.

[8]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[9]  S. Wagner,et al.  In vitro variables of apheresis platelets are stably maintained for 7 days with 5% residual plasma in a glucose and bicarbonate salt solution, PAS‐5 , 2012, Transfusion.

[10]  J. Sweeney,et al.  Current status of additive solutions for platelets , 2012, Journal of clinical apheresis.

[11]  L. Goodnough,et al.  Complement (C1q) fixing solid‐phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patients , 2011, Transfusion.

[12]  M. Delaney,et al.  Humoral immunomodulatory effect of influenza vaccine in potential blood donors: implications for transfusion safety , 2011, Transfusion medicine.

[13]  P. Perseghin.  High concentration plasma-reduced plateletapheresis concentrates. , 2011, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[14]  W. Flegel,et al.  A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high‐titer ABO antibodies , 2011, Transfusion.

[15]  J. Adamson,et al.  In vitro and in vivo evaluation of apheresis platelets stored for 5 days in 65% platelet additive solution/35% plasma , 2010, Transfusion.

[16]  N. Heddle,et al.  Posttransfusion platelet count increments after ABO‐compatible versus ABO‐incompatible platelet transfusions in noncancer patients: an observational study , 2010, Transfusion.

[17]  N. Heddle,et al.  Practices associated with ABO‐incompatible platelet transfusions: a BEST Collaborative international survey , 2010, Transfusion.

[18]  Jeffrey McCullough,et al.  Dose of prophylactic platelet transfusions and prevention of hemorrhage. , 2010, The New England journal of medicine.

[19]  C. Hillyer,et al.  ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies. , 2010, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[20]  G. Naglie,et al.  ABO‐identical versus nonidentical platelet transfusion: a systematic review , 2009, Transfusion.

[21]  P. Scheinberg,et al.  Probiotic‐associated high‐titer anti‐B in a group A platelet donor as a cause of severe hemolytic transfusion reactions , 2009, Transfusion.

[22]  R. Davenport,et al.  Anti‐A and anti‐B titers in pooled group O platelets are comparable to apheresis platelets , 2008, Transfusion.

[23]  M. Fung,et al.  Transfusion of platelets containing ABO-incompatible plasma: a survey of 3156 North American laboratories. , 2009, Archives of pathology & laboratory medicine.

[24]  L. Cooling.  ABO and platelet transfusion therapy , 2007, Immunohematology.

[25]  Guidelines for the use of platelet transfusions , 2003, British journal of haematology.

[26]  Laurence Klotz.  Reactions , 2002, The Lancet.